What prognostic factors are important in duodenal adenocarcinoma?

Bakaeen, F G; Murr, M M; Sarr, M G; Thompson, G B; Farnell, M B; Nagorney, D M; Farley, D R; van Heerden, J A; Wiersema, L M; Schleck, C D; Donohue, J H

Bakaeen, F G; Murr, M M; Sarr, M G; Thompson, G B; Farnell, M B; Nagorney, D M; Farley, D R; van Heerden, J A; Wiersema, L M; Schleck, C D; Donohue, J H.

Affiliation

Bakaeen FG; Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minn. 55905, USA.

Arch Surg ; 135(6): 635-41; discussion 641-2, 2000 Jun.

Article in En | MEDLINE | ID: mdl-10843358

Subject(s)

Adenocarcinoma/mortality; Adenocarcinoma/surgery; Duodenal Neoplasms/mortality; Duodenal Neoplasms/surgery; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Pancreaticoduodenectomy; Retrospective Studies; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Duodenal Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Arch Surg Year: 2000 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links